Literature DB >> 22977531

Evaluation of the combined expression of chemokine SDF-1α and its receptor CXCR4 as a prognostic marker for gastric cancer.

Hyo Jin Lee1, Song Mei Huang, Ha Yon Kim, Yoon Suk Oh, Ji Young Hwang, Zhe Long Liang, Jeong Ki Min, Hwan Jung Yun, Ji Young Sul, Samyong Kim, Deog Yeon Jo, Jin Man Kim.   

Abstract

Chemokine stromal cell-derived factor (SDF)-1α and its receptor CXC chemokine receptor 4 (CXCR4) have been shown to impact cancer progression. Accumulating evidence suggests that CXCR4 and SDF-1α expression is useful for evaluating the risk of gastric cancer progression. Thus, combined analysis of SDF-1α and CXCR4 should have high prognostic potential as a molecular marker for gastric cancer. We investigated the expression of SDF-1α and CXCR4 using immunohistochemistry in relation to prognosis, clinicopathological features and clinical outcomes in 221 cases of primary gastric cancer. Patients were categorized into three groups according to CXCR4 and SDF-1α expression: high CXCR4/high SDF-1α, low CXCR4/low SDF-1α, and high CXCR4/low SDF-1α - low CXCR4/high SDF-1α. No significant differences were noted in age, gender, histology, tumor location, lymphovascular invasion or proportion of tumor size >5 cm among the three groups. However, high CXCR4/high SDF-1α expression in tumor cells was significantly associated with depth of invasion of the tumor, lymph node involvement, and higher tumor stage compared to tumors with low CXCR4/low SDF-1α expression or high CXCR4/low SDF-1α - low CXCR4/high SDF-1α expression. Furthermore, patients with high CXCR4/high SDF-1α expression had the worst patient prognosis, whereas patients who had low CXCR4/low SDF-1α expression showed the most favorable prognosis. In conclusion, CXCR4 and SDF-1α are useful prognostic factors in gastric cancer, and the combination of high CXCR4 protein expression with high SDF-1α expression suggests a dismal prognosis.

Entities:  

Year:  2011        PMID: 22977531      PMCID: PMC3440693          DOI: 10.3892/etm.2011.228

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

1.  Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

2.  The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways.

Authors:  R K Ganju; S A Brubaker; J Meyer; P Dutt; Y Yang; S Qin; W Newman; J E Groopman
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 5.  Chemokines: key players in cancer.

Authors:  M Arya; H R H Patel; M Williamson
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

6.  Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer.

Authors:  Carl C Schimanski; Stefan Schwald; Nektaria Simiantonaki; Caren Jayasinghe; Ursula Gönner; Vanessa Wilsberg; Theodor Junginger; Martin R Berger; Peter R Galle; Markus Moehler
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

7.  CXC chemokine receptor 4 expression and function in human astroglioma cells.

Authors:  J W Oh; K Drabik; O Kutsch; C Choi; A Tousson; E N Benveniste
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

8.  Expression of CXCL12 and CXCR4 in pT3-stage gastric cancer does not correlate with peritoneal metastasis.

Authors:  Kenji Tsuboi; Yasuhiro Kodera; Hayao Nakanishi; Seiji Ito; Yoshinari Mochizuki; Goro Nakayama; Masahiko Koike; Michitaka Fujiwara; Yoshitaka Yamamura; Akimasa Nakao
Journal:  Oncol Rep       Date:  2008-11       Impact factor: 3.906

9.  Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells.

Authors:  Isaya Hashimoto; Keiichi Koizumi; Mikiko Tatematsu; Takayuki Minami; Seiji Cho; Nobuhiro Takeno; Akitoshi Nakashima; Hiroaki Sakurai; Shigeru Saito; Kazuhiro Tsukada; Ikuo Saiki
Journal:  Eur J Cancer       Date:  2008-03-28       Impact factor: 9.162

Review 10.  Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors.

Authors:  Carl C Schimanski; Peter R Galle; Markus Moehler
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

View more
  8 in total

Review 1.  Inflammation-related factors predicting prognosis of gastric cancer.

Authors:  Wen-Jun Chang; Yan Du; Xin Zhao; Li-Ye Ma; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

Review 2.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

3.  The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis.

Authors:  Mingzhi Han; Shunzeng Lv; Ya Zhang; Ruiyang Yi; Bin Huang; Hanhui Fu; Ruixiang Bian; Xingang Li
Journal:  Tumour Biol       Date:  2014-01-25

4.  Elevated level of some chemokines in plasma of gastric cancer patients.

Authors:  Monika Baj-Krzyworzeka; Kazimierz Węglarczyk; Jarek Baran; Antoni Szczepanik; Mirosław Szura; Maciej Siedlar
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

Review 5.  Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.

Authors:  Li-Jun Xue; Xiao-Bei Mao; Li-Li Ren; Xiao-Yuan Chu
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

6.  lncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR4 and RhoA signaling pathway.

Authors:  Jun Xiao; Hao Lai; Sheng-Hong Wei; Zai-Sheng Ye; Fu-Sheng Gong; Lu-Chuan Chen
Journal:  Cancer Med       Date:  2019-09-13       Impact factor: 4.452

7.  The Expression and Prognostic Significance of VEGF and CXCR4 in Gastric Cancer: Correlation with Angiogenesis, Lymphangiogenesis and Progression.

Authors:  Łukasz Kruszyna; Dawid Murawa; Paweł Piotr Jagodziński; Grzegorz Oszkinis; Zbigniew Krasiński
Journal:  Curr Issues Mol Biol       Date:  2022-07-06       Impact factor: 2.976

8.  Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection.

Authors:  Xuefei Wang; Heng Zhang; Hongyong He; Zhenbin Shen; Zhaoqing Tang; Jiejie Xu; Yihong Sun
Journal:  Cancer Sci       Date:  2014-10-04       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.